Monday, June 2, 2014
CDC's recommendation of Truvada for HIV pre-exposure
prophylaxis is unlikely to trigger an explosion in prescriptions for the drug,
despite estimates that as many as half a million people could be candidates in
If all those candidates
actually got the drug for one year, the cost would be $7.8 billion. But that is
unlikely to happen, because CDC's recommendation does not address several of
the barriers that have limited uptake.